Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
NCT05387837
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Neovascular Age-related Macular Degeneration
Diabetic Macular Edema
Interventions
DRUG:
D-4517.2
Sponsor
Ashvattha Therapeutics, Inc.